Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ABR-238901是一种可口服的、有作用的 S100A8/A9阻滞剂,对 S100A8/A9与其受体 RAGE(晚期糖基化终产物受体)和TLR4 (toll 样受体4)的相互作用具有抑制作用。ABR-238901具有作为治疗心肌梗死(MI)化合物的潜力。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 996 | 现货 | ||
5 mg | ¥ 2,660 | 现货 | ||
10 mg | ¥ 3,930 | 现货 | ||
25 mg | ¥ 6,420 | 现货 | ||
50 mg | ¥ 8,790 | 现货 | ||
100 mg | ¥ 11,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,920 | 现货 |
产品描述 | ABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI). |
体内活性 | ABR-238901, given at a dose of 30 mg/kg/day through gavage over a period of 3 weeks, demonstrates reduced angiogenesis and lowered levels of IL6 and IL10 in MDSCs [1]. When ABR-238901 (30 mg/kg/day via gavage) is combined with Bortezomib (0.6 mg/kg via subcutaneous injection, twice a week), it leads to a decreased tumor burden compared to using either agent alone [1]. In C57BL/6NRJ mice with myocardial ischemia resulting from permanent coronary artery ligation, ABR-238901 administered at a dose of 30 mg/kg via intraperitoneal injection for the initial 3 days, followed by continuous oral administration daily for 21 days, induces progressive deterioration of cardiac function and accelerates left ventricular remodeling. However, when ABR-238901 is administered during the first 3 days post-myocardial infarction, it limits inflammatory damage and promotes a reparative environment [2]. |
分子量 | 394.63 |
分子式 | C11H9BrClN3O4S |
CAS No. | 1638200-22-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 0.1 mg/mL (insoluble), Sonication and heating to 60℃ are recommended.
DMSO: 30.0 mg/mL (76.0 mM), Sonication and heating to 60℃ are recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.534 mL | 12.6701 mL | 25.3402 mL | 63.3505 mL |
5 mM | 0.5068 mL | 2.534 mL | 5.068 mL | 12.6701 mL | |
10 mM | 0.2534 mL | 1.267 mL | 2.534 mL | 6.335 mL | |
20 mM | 0.1267 mL | 0.6335 mL | 1.267 mL | 3.1675 mL | |
50 mM | 0.0507 mL | 0.2534 mL | 0.5068 mL | 1.267 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ABR-238901 1638200-22-2 Immunology/Inflammation TLR ABR238901 ABR 238901 Inhibitor inhibitor inhibit